Autoimmune Skin Diseases
Products may not be approved for sale as in vitro diagnostics in all countries.
Please contact us for further details.
Customers in the US, please contact MBL International Corporation for details. ⇒
|MESACUP™-2 TEST Desmoglein 1||7881E||48 wells||ELISA|
|MESACUP™-2 TEST Desmoglein 3||7886E||48 wells||ELISA|
|MESACUP™ BP180 TEST||7697E||48 wells||ELISA|
|MESACUP™ BP230 TEST||7614E||48 wells||ELISA|
: CE-marked In vitro Diagnostic Reagent
MESACUP™-2 TEST Desmoglein 1
The MESACUP™-2 TEST Desmoglein 1 measures anti-Dsg1 antibodies present in the serum by ELISA.
Desmoglein 1 (Dsg1) is a desmosomal cadherin expressed in stratified squamous epithelia and the target antigen in pemphigus foliaceus (PF). PF is an autoimmune blistering disease of skin and characterized clinically by small flaccid blisters and scaly, crusted erosions, and histologically by intraepidermal blister formation due to loss of cell adhesion of keratinocytes. Anti-Dsg1 IgG autoantibodies are detected in sera from patients with PF and play a pathogenic role in blister formation in PF.
MESACUP™-2 TEST Desmoglein 3
The MESACUP™-2 TEST Desmoglein 3 measures anti-Dsg3 antibodies present in the serum by ELISA.
Desmoglein 3 (Dsg3) is a desmosomal cadherin expressed in stratified squamous epithelia and the target antigen in pemphigus vulgaris (PV). PV is a fatal autoimmune blistering disease of the skin and mucous membrane and clinically characterized by flaccid blisters and widespread painful erosions.
Anti-Dsg3 IgG is not found in patients with PF, another type of pemphigus.
MESACUP™ BP180 TEST
The MESACUP™ BP180 TEST is for measuring anti-BP180 autoantibodies in patient serum.
Bullous pemphigoid (BP) is a chronic itchy blistering skin disorder found mainly in the elderly population and is characterized by frequent occurring of tense blisters and erythema. Target antigens of the autoantibodies in BP patient serum are BP230 and BP180, also called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and180 kD respectively.
BP180 is thought to be the direct target of the autoantibody because of its location, and the autoantibodies against BP230 are thought to be secondarily produced.
MESACUP™ BP230 TEST
The MESACUP™ BP230 TEST has recombinant protein of both N-terminus and C-terminus of BP230 as solid phase and measures anti-BP230 autoantibodies in patient serum.
Anti-BP180 is thought to be the pathogenic autoantibody, however, not all BP patients have anti-BP180 antibody in their serum. Anti-BP230 antibody is considered to be a useful serologic marker of the disease.